# JiaRay Group

Source: https://onco.cc/companies/jiaray-group/  
OnCo record `jiaray-group` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JiaRay Group is developing JR8603, a chemotherapy drug attached to a short peptide that is meant to be cut free only inside tumours by an enzyme called legumain. It is in a first trial in people with advanced solid tumours, including stomach and bowel cancer.

## Summary

JiaRay Group is a family of companies developing tumour-targeted peptide-drug conjugates: JiaRay Therapeutics, Inc., in the San Diego area (Encinitas, California), runs IND-enabling and clinical development; JiaRay Biopharmaceuticals, Ltd., in Jiangsu Province, China, founded in 2013, runs early discovery; and JiaRay Pharmaceuticals, Inc., a Cayman Islands holding company founded in 2016, owns rights outside China. Chief executive Sam Chu founded JiaRay in 2013, according to the company. Its approach uses legumain, an asparaginyl endopeptidase that the company says is overexpressed and active in most solid tumours, on tumour blood vessels and on tumour-associated macrophages, to release a cytotoxic payload from an asparagine-containing peptide linker. The lead candidate JR8603 is a small-molecule peptide-drug conjugate given intravenously; its first-in-human escalation and expansion study in advanced solid tumours, including gastric, oesophagogastric junction and colorectal cancers, is registered as NCT06783569. Its first registered cancer trial, NCT06783569, was posted on ClinicalTrials.gov in January 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: JiaRay Therapeutics, Inc.; JiaRay Biopharmaceuticals, Ltd.; JiaRay Pharmaceuticals, Inc.
- HQ: Encinitas, CA
- Type: biotech
- Website: https://jiaraygroup.com/

## Notes

- The company website's pipeline page still describes JR8603 as completing IND-enabling work, so it predates the registered trial.
- The company homepage at the time of reading carried unrelated injected online-gambling content, which suggests the site is compromised; the about, science, pipeline, team and contact pages were read separately.
- Legumain is not a target record in the corpus, so no target id is set.
- No financing information was found; none is recorded.
- Company website read on 29 October 2026.

## Sources

- Official website: https://jiaraygroup.com/
- About the JiaRay companies: https://jiaraygroup.com/jiaray-group/
- ClinicalTrials.gov: first-in-human escalation and expansion study of JR8603 (NCT06783569): https://clinicaltrials.gov/study/NCT06783569

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Peptide-drug & small-molecule-drug conjugates](https://onco.cc/technologies/peptide-drug-conjugate/)

---
JSON: https://onco.cc/api/v1/entities/jiaray-group.json